Clinical Trial Detail

NCT ID NCT02110355
Title A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Amgen
Indications

melanoma

Therapies

KRT-232 + Trametinib

Dabrafenib + KRT-232 + Trametinib

Dabrafenib + Trametinib

Age Groups: adult

No variant requirements are available.